Overcoming Challenges and Building a Successful Company:

Dr. Gautam Ghatnekar, CEO of FirstString Research, shares his secrets to raising capital, recruiting and retaining talent, and overcoming the challenges of getting medicines to the market.

Recently, we sat down for a chat with Dr. John Atkinson, Founder and CEO of Atkinson Toxicology Consulting and former President of the American College of Toxicology (ACT). Listen as Dr. Atkinson shares his journey in the drug development industry, his experience as the former President of the ACT, what to look for in a partner CRO, and much more.

Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept.

Listen in as we discuss the role of a strategic business development consultant in drug development with industry veteran Teresa Johnk, Founder and CEO of BioPharma Connections.

In this podcast, we uncover:

• Important considerations to secure VC funding

• How to ensure the successful program completion

• What to look for in a consultant

• What to look for in a CRO/CDMO partner

Altasciences’ important role in the drug development process comes with the significant responsibility of ensuring the welfare of our research animals, a responsibility that we take extremely seriously.

Altasciences is committed to doing everything possible to minimize the number of animals used and ensure that the animals used are treated with care, dignity, and the utmost respect.

Dr. Christina Cruzen, Attending Veterinarian and Chief Animal Welfare Officer, had the opportunity to interview Dr. Megan R. LaFollette, Program Manager at The North American 3Rs of Animals in Research Collaborative (NA3RsC), to discuss the importance of animal welfare, the 3Rs, how the role of animal research is changing, rat tickling as a refinement technique, and much more.

EPISODE #16 - Altasciences Scientific Experts Discuss Safety Pharmacology by The Altascientist

EPISODE #15 - Altasciences’ Commitment to the 3Rs with Dr. Christina Cruzen and Shayna Halverson by The Altascientist

EPISODE #14 - Three Laboratories - One Vision, with Dr. Lynne Le Sauteur by The Altascientist

Paul Sidney, Senior Director, Compliance and Regulatory Affairs, and Julie Forget, Director, Safety Assessment, present a comparison of the U.S. FDA and Health Canada CTA submission process to support first-in-human phase I clinical trials.

Learn more about:

• How data from nonclinical studies in support of an IND submissions is submitted to foreign receiving authorities

• The Clinical Trial Application review process (what to include and expected timelines)

• The differences and similarities between the U.S. FDA and Health Canada

Interview with Dr. Anahita Keyhani, Altasciences with Mike Lee and Neil Spooner from CPSA Everyday

EPISODE #11: Overcoming the Challenges of Manufacturing and Clinical Trials by The Altascientist